Syndax Pharmaceuticals

US · SNDX #2947 by market cap Listed 2016

17.03 -0.34 -1.96%

Live - 5344 symbols - heartbeat 241s ago · 2026-10-08 05:22

Pre-market 16.95 -0.46%

After-hours 17.20 +1.00%

Market cap: 1.52B
P/E (TTM): -6.78
P/B: 100.77
EPS: -3.29
Div yield: 0.00%
52W pos: 32%

Reader sentiment Are you bullish or bearish on SNDX?

Anonymous reader poll. Unscientific, not investment advice.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include Revuforj and Niktimvo. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Founded: 2005
CEO: Mr. Michael A. Metzger
Employees: 277
Headquarters: New York, New York, United States of America
Fiscal year end: 12-31
Website: syndax.com

Company profile

Exchange: US
Symbol: SNDX
Market-cap rank: #2947
Listing date: 2016-03-03
Market cap: 1.52B
Float cap: 1.37B
Shares out: 89.30M
Float shares: 80.30M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 05:22:06 · For reference only, not investment advice and not tailored to your situation.